Figure 5 Risk factor control in the intensive treatment group

Slides:

Advertisements

Similar presentations

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.

Advertisements

Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.

Copyright © 2005 American Medical Association. All rights reserved.

Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline.

Copyright © 2017 American Academy of Pediatrics.

Nat. Rev. Nephrol. doi: /nrneph

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

with undiagnosed diabetes mellitus by three diagnostic criteria

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 4 Effect of dapagliflozin on HbA1c and body weight

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Evidence for the incretin effect and

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The sensory and secretory function of the L cell

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 5 Comparison of outcomes with belimumab or rituximab therapy

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Figure 1 Acute kidney injury and chronic kidney disease

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Figure 4 Effects of glucagon-like peptide 1 (GLP-1) and

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Need for better diabetes treatment for improved renal outcome

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Diabetes /care in Grampian

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

Kotseva K, et al. Lancet 2009;373:929-40

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Nat. Rev. Nephrol. doi: /nrneph

Pathway to initial antihypertensive therapy in patients with diabetes

Presentation transcript:

Figure 5 Risk factor control in the intensive treatment group of the Steno-2 trial in patients with type 2 diabetes mellitus and microalbuminuria151 Figure 5 | Risk factor control in the intensive treatment group of the Steno-2 trial in patients with type 2 diabetes mellitus and microalbuminuria151. Percentage of patients in the intensive therapy group (n = 80) who did not reach the intensive treatment goals at a mean follow-up of 7.8 years. To convert values for cholesterol to mmol/l, multiply by 0.02586. To convert values for triglycerides to mmol/l, multiply by 0.01129. BP, blood pressure; HbA1c, haemoglobin A1c. Muskiet, M. H. A. et al. (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.123